000			03116cam a2200361 i 4500
001			on1091999679
003			OCoLC
005			20220822144248.0
008			180316t20192018enk e b 001 0 eng d
020			_a9781509868087 _q(paperback)
020			_a1509868089 _q(paperback)
029	0		_aAU@ _b000065146890
029	1		_aAU@ _b000065199025
035			_a(OCoLC)1091999679 _z(OCoLC)1111084400
040			_aAU@ _beng _erda _cAU@ _dOCLCO _dOCLCF _dU3W _dOCLCQ _dOCL _dOMB _dAUPTL _dOCLCQ _dOCLCO
043			_an-us---
050		4	_aHD9995.H424 _bT44 2019
082	0	4	_a338.7 _223
100			_aCarreyrou, John, _eauthor. _951545
245	1	0	_aBad blood : _bsecrets and lies in a Silicon Valley startup / _cJohn Carreyrou.
260			_aLondon _bPicador, an imprint of Pan Macmillan _c [2018]
300			_ax, 339 pages ; _c20 cm
500			_aOriginally published: 2018.
504			_aIncludes bibliographical references (pages 305-324) and index.
505	0		_aA purposeful life -- The gluebot -- Apple envy -- Goodbye East Paly -- The childhood neighbor -- Sunny -- Dr. J -- The miniLab -- The wellness play -- "Who is LTC Shoemaker?" -- Lighting a Fuisz -- Ian Gibbons -- Chiat\Day -- Going live -- Unicorn -- The grandson -- Fame -- The Hippocratic Oath -- The tip -- The ambush -- Trade secrets -- La Mattanza -- Damage control -- The empress has no clothes -- Epilogue -- Afterword.
520			_aThe full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley
610		0	_aTheranos (Firm) _xHistory. _951546
650		0	_aHematologic equipment industry _zUnited States. _951547
650		0	_aFraud _zUnited States. _951548
651		7	_aUnited States. _2fast
942			_2ddc _cNONFIC
948			_hNO HOLDINGS IN NZWMT - 84 OTHER HOLDINGS
999			_c47547 _d47547